Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

SIMPLE SUMMARY: Myelosuppression is a side effect of chemotherapy, in which the production of red and white blood cells and platelets is reduced, increasing risk of infections. Blinatumomab, a bispecific T-cell engager (BiTE(®)) molecule, is a novel anticancer drug that kills acute lymphoblastic leu...

Descripción completa

Detalles Bibliográficos
Autores principales: Kantarjian, Hagop M., Zugmaier, Gerhard, Brüggemann, Monika, Wood, Brent L., Horst, Heinz A., Zeng, Yi, Martinelli, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616108/
https://www.ncbi.nlm.nih.gov/pubmed/34830762
http://dx.doi.org/10.3390/cancers13225607

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616108/
https://www.ncbi.nlm.nih.gov/pubmed/34830762
http://dx.doi.org/10.3390/cancers13225607

Ejemplares similares